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Ghrelin was initially identified as an endogenous ligand for the GH secretagogue receptor. When
administrated exogenously, ghrelin stimulates GH release and food intake. Previous reports in
ghrelin-nullmice,whichdonotexhibit impairedgrowthnorappetite,questionthephysiologic role
ofghrelin in the regulationof theGH/IGF-I axis. In this study,wegenerateda transgenicmouse that
expresses human diphtheria toxin (DT) receptor (DTR) cDNA in ghrelin-secretion cells [ghrelin-
promoter DTR-transgenic (GPDTR-Tg) mice]. Administration of DT to this mouse ablates ghrelin-
secretion cells in a controlledmanner. After injection of DT into GPDTR-Tgmice, ghrelin-secreting
cells were ablated, and plasma levels of ghrelin were markedly decreased [nontransgenic litter-
mates, 70.6  10.2 fmol/ml vs. GPDTR-Tg, 5.3  2.3 fmol/ml]. To elucidate the physiological roles
of circulating ghrelin on GH secretion and somatic growth, 3-wk-old GPDTR-Tgmice were treated
withDT twiceaweek for5wk. TheGHresponses toGHRH inmaleGPDTR-Tgmicewere significantly
lower than those inwild-typemice at 5wkof age. However, thosewere normalized at 8wkof age.
In contrast, in female mice, there was no difference in GH response to GHRH between GPDTR-Tg
mice and controls at 5or 8wkof age. Thegender-dependentdifferences in response toGHRHwere
observed in ghrelin-ablated mice. However, GPDTR-Tg mice did not display any decreases in IGF-I
levels or anygrowth retardation.Our results strongly suggest that circulatingghrelin does not play
a crucial role in somatic growth. (Endocrinology 151: 1743–1750, 2010)
GH secretion is predominantly regulated by two hy-pothalamic peptides, one factor is GHRH and a sec-
ond is somatostatin (SST). In 1999, Kojima et al. (1) dis-
covered ghrelin as an endogenous ligand for the GH
secretagogue receptor (GHS-R or ghrelin receptor) from
rats’ stomach. Ghrelin, an acylated peptide of 28 amino
acids, is synthesized primarily in endocrine cells of the
stomach, named X/A-like or ghrelin cells (2). Peripheral
administration of ghrelin strongly stimulates GH secre-
tion (1, 3). Because coadministration of GHRH and
ghrelin produces synergistic effects on pituitary GH re-
lease (4), circulating ghrelin may play a role in augmen-
tation of GHRH-stimulated GH pulses. Therefore, circu-
lating ghrelin was thought to be the third peptide which
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regulates GH secretion. Indeed, patients with a functional
mutation in GHS-R, ghrelin receptor, display familial
short stature (5). Okimura et al. (6), however, demon-
strated that circulating ghrelin levels do not correlated
with those of GH; also, administration of a GHS antago-
sist to freelymoving rats did not reduce plasmaGH levels.
Ghrelin knockout mice also exhibit normal growth pat-
terns (7). On the other hand, ghrelin receptor knockout
mice exhibit modest, but significant, body weight reduc-
tions anddecreased serum IGF-I levels (8). Together, these
findings question the physiologic significance of ghrelin in
the regulationofGHsecretion.As alwayswith suchmodel
mice, there may be confounding factors, such as develop-
mental adaptation and other compensatory mechanisms.
To avoid these factors, it may be necessary to ablate gh-
relin after birth or before puberty. Moreover, during the
prepubertal and pubertal period, GH-dependent propor-
tional body growth is observed in manymammalian spe-
cies. The fetal growth is GH-independent, and growth
during the early postnatal is only partial dependent upon
GH. Therefore, to evaluate whether an absence of circu-
lating ghrelin can influence a somatic growth throughGH/
IGF-I axis modification, we think that it is appropriate to
choose a postweaning model.
In this study, we adopted a diphtheria toxin (DT) re-
ceptor (DTR)-mediated conditional and targeted cell ab-
lation strategy to ablate ghrelin secretion cells, X/A-like
cell, in a specific and controlledmanner (9).We generated
a transgenicmouse expressing humanDTR cDNA,which
encodes humanheparin-binding epidermal growth factor-
like growth factor (HB-EGF), under the control of the
transcriptional regulatory regions of ghrelin. In this
mouse, ghrelin-secreting cells express thehumanDTRand
can be ablated after the administration of a small amount
ofDT. By using this transgenicmouse, we ablated ghrelin-
secretion cells afterweaning,which allowed us to evaluate
the physiologic significance of ghrelin inGHsecretion and
somatic growth.
Materials and Methods
All animal experiments were approved by the Kyoto University
Graduate School of Medicine Committee on Animal Research.
Procedures were performed in accordance with the principles
and guidelines established by that committee.
Plasmid construction and generation of transgenic
mice [ghrelin-promoter DTR-transgenic (GPDTR-Tg)
mice]
The pGPDTRplasmidwas constructed by replacement of the
mouse albumin enhancer/promoter region of pMS7 (9) with a
4.1-kbMulI-HindIII fragment containing the 5-flanking region
of the human ghrelin gene (4110/33) derived from the
p-4110/-33GHRE plasmid (human ghrelin promoter in pGL3)
(Fig. 1A) (10). The 6.4-kbNotI-XhoI fragment of pGPDTRwas
microinjected into the pronucleus of fertilized eggs obtained
fromC57/B6mice (SLC, Shizuoka, Japan). The viable eggs were
transferred into the oviducts of pseudopregnant female ICRmice
(Japan CLEA, Osaka, Japan) by using standard techniques (11).
Founder transgenic mice, identified by PCR analysis, were bred
withC57BL/6mice.Micewere housed in air-conditioned animal
quarters, with light between 0800 and 2000 h. Except where
noted, animals were fed standard rat chow (CE-2, 352 kcal/100 g;
Japan CLEA) and water ad libitum.
Semiquantitative PCR
Total RNA was extracted using a Sepasol-RNA kit (Nacalai
Tesque, Kyoto, Japan). RT used a high capacity cDNA RT kit
(Applied Biosystems, Foster City, CA).
Semiquantitative PCR determined the distribution of the
DTR in GPDTR-Tg mice, using the following primers: sense
5-CCTCCTCTCGGTGCGGG-3 and antisense 5-AGTCAC-
CAGTGCCGAGAGAACTG-3. Thirty-five cycles of thermal
was performed with 94 C for 30 sec, 55 C for 30 sec, and 72 C
for 30 sec.Human heartmRNA (purchased fromClontech, Palo
Alto, CA) was used as a positive control.
DT injection
DT was purchased from Sigma-Aldrich Japan (Tokyo,
Japan). According to the previous report using DTR-mediated
cell ablation systems (9), DT was injected im.
Histological procedures
Formalin-fixed, paraffin-embedded tissue sections were im-
munostained using avidin-biotin peroxidase complex methods
(Vectastain “ABC” Elite kit; Vector Laboratories, Burlingame,
CA) as described (11). Sections were incubated overnight at 4 C
with antighrelin-(1–11) antiserum that specifically recognizes
acylated ghrelin (final dilution, 1:5000). Tissue sections were
also stained with hematoxylin and eosine.
Measurement of plasma ghrelin levels
Measurement of plasma ghrelin levels was performed as re-
ported previously (12). Blood samples drawn from the retro-
orbital vein at 1000 h were immediately transferred to chilled
siliconized glass tubes containing Na2EDTA (1 mg/ml) and
FIG. 1. Generation of GPDTR-Tg mice. A, The GPDTR-Tg construct
contained a fusion gene comprised of the 5flanking lesion of human
ghrelin (4085 bp) and the DTR cDNA (human HB-EGF). B, Expression of
DTR mRNA in various tissues of GPDTR-Tg mice at 8 wk of age. The
human heart mRNA was used as a positive control.
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aprotinin (1000 KIU/ml; Ohkura Pharmaceutical, Kyoto,
Japan). After centrifugation at 4 C to separate out the plasma,
hydrochloric acid was added to samples at a final concentration
of 0.1 N. Plasma was immediately frozen and stored at 80 C
until assayed. Plasma ghrelin concentrations were determined
using a ghrelin ELISA kit (Mitsubishi Kagaku Iatron, Tokyo,
Japan).
Real-time PCR analysis
Extraction of total RNA from various tissues and RT was
performed as described above. Real-time quantitative PCR used
an ABI PRISM 7500 Sequence Detection System (Applied Bio-
systems) using the primers and TaqMan probes described in Ta-
ble 1.ThemRNAexpression levels of each genewere normalized
to that of 18S rRNA. All samples were examined in triplicate in
96-well plates using an ABI Prism 7500 sequence detector ac-
cording to the manufacturer’s protocol.
GH provocative test
GH provocative test was carried out as previously described
(12). These experiments were conducted in unanesthelizedmice.
HumanGHRHwaspurchased fromSumitomoPharmaceuticals
Co.,Ltd. (Osaka, Japan). Serumsampleswere collectedat15and
30 min after sc injection of 180 mcg/kg of GHRH.
Ghrelin-rescue experiments
Osmotic infusion pumps (Alzet Micro-Osmotic pump,
Model 1002;DurectCorp., Cupertino,CA)were implanted sc in
3-wk-old male GPDTR-Tg mice. Ghrelin (60 mcg/kgd; Peptide
Institute, Osaka, Japan) or saline was continuously infused
through the osmotic infusion pumps. Then mice were started to
treat with DT (50 ng/kg twice a week) a day after pump implan-
tation. The average plasma ghrelin levels during continuous in-
fusion of ghrelin were 31.6  5.3 fmol/ml in the DT-treated
GPDTR-Tg mice, whereas those without ghrelin infusion were
1.7 0.2 fmol/ml. GHprovocative test were carried out in these
mice at the age of 5 wk.
Measurement of serum GH and IGF-I levels
Blood samples were collected from the tail veins of mice.
Serum was isolated by centrifugation and stored at20 C until
assayed. Serum GH levels and IGF-I levels were measured using
the appropriate EIA kits from SPI-BIO (Bonde, France) and Di-
agnostic Systems Laboratories, Inc. (Webster, TX), respectively,
according to the manufacturers’ instructions.
Measurement of body lengths
Mouse body lengthwasmeasured bymanual immobilization
and extensionofmice to determine nose-to-anus length.Allmea-
surements were performed by the same individual in a blind
fashion.
Measurement of fat mass and bone mineral
density (BMD)
The fat mass (% fat) and BMD of mice were measured by
computed tomography (CT) (Laboratory CT; Lacita, Aloka,
Japan) under pentobarbital anesthesia.
Statistical analysis
Results are expressed as the means SEM. Multiple compar-
isons between groups were made by Turkey-Krammer test, with
 set atP0.05.The resultsonbodyweight and serumGHlevels
after GHRH injection were analyzed by a two-way ANOVA
followed by Tukey’s post hoc test, with  set at P  0.05. Sta-
tistical analyses were carried out with STATVIE 4.0 software
(Abacus Concepts, Inc., Berkley, CA).
Results
Generation of transgenic mice in which ghrelin
can be ablated in a controlled manner
Transgenic mice
To elucidate physiologic role of ghrelin inGHsecretion
and somatic growth, we developed transgenic mice in
which ghrelin can be ablated in controlled manner. We
adopted a DTR-mediated conditional and targeted cell
ablation strategy. We created transgenic mice that ex-
pressed the gene for the human DTR, human HB-EGF,
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under the control of the ghrelin promoter. By injecting
transgenes into 184 eggs, we obtained three lines of trans-
genic mouse (Tg 1-2, Tg 5-1, and Tg 5-8). We continued
with theTg5-1 transgenic line, becauseTg1-2 animals did
not exhibit decreases in plasma ghrelin levels after injec-
tionof high-doseDTandTg5-8 requiredhighdoses ofDT
(50 mcg/kg) to ablate ghrelin-producing cells (data not
shown). In Tg 5-1 transgenic animals, semiquantitative
PCR analysis revealed high expression of DTR mRNA in
the stomach and weak expression in the duodenum and
jejunum.Noexpression, however, could be detected in the
ileum, colon, pancreas, hypothalamus, pituitary, liver, or
lung (Fig. 1B). In Tg 5-1 mice, the ghrelin-producing cells
of the stomach were ablated by injection with low-dose
DT (10 or 50 ng/kg) (Fig. 2, A, B, and D). We therefore
designated the Tg 5-1 transgenic line and nontransgenic
littermates as GPDTR-Tg mice and wild-type (WT) mice,
respectively.
Ablation of ghrelin-producing cell
To determine the dose and timeframe of DT injection,
preliminarily studies were performed: GPDTR-Tg mice
were injected with saline or DT twice a week at a dose of
10, 30, 50, 100, and 500 ng/kg (on d 0 and 2). Plasma
ghrelin levels on d 4 were decreased to approximately
60, 30, 5, 5, and 5% of control mice (Tg mice treated
with saline) after 10, 30, 50, 100, and 500 ng/kg of DT
injection, respectively. Thus, we judged that 50 ng/kg of
DT is the smallest effective dose to reduce plasma
ghrelin. The final results using 10 and50ng/kg ofDTwere
described below. Next, GPDTR-Tg mice were injected
with 50 ng/kg of DTwith four schedules: once a week (on
d 0), twice a week (on d 0 and 2), three times a week (on
d 0, 2, and 4), or daily (from d 0 to 6), and plasma ghrelin
levels were measured on d 7. The once-a-week injection
ofDTwas insufficient, but the twice-a-week injection of
DT had enough effect on reduction in plasma ghrelin
concentration.
To ablate ghrelin-producing cells, 8-wk-old male WT
andGPDTR-Tgmicewere injected imwith 10 or 50 ng/kg
DT daily on d 0 and 2 and analyzed on d 4. WT mice
treated with saline or DT and GPDTR-Tg mice treated
with saline were used as control mice.
To evaluate the effects of DT injection on ghrelin-pro-
ducing cell, we analyzed stomach by immunohistochem-
ical analysis with antighrelin antisera (Fig. 2A) and real-
time PCR (Fig. 2, B and C). DT injection reduced in a
dose-dependent manner both the number of ghrelin-pos-
itive cells and the expressionof ghrelinmRNA in the stom-
ach of GPDTR-Tgmice (Fig. 2, A and B). DT injection did
not produce in any abnormalities in WT mice, because
these mice do not possess the DTR, making them insen-
sitive to DT. In transgenic animals, DT injection also re-
ducedghrelinmRNAexpression in theduodenum,butnot
the pancreas, pituitary, or hypothalamus (Fig. 2C).
Plasma ghrelin levels in GPDTR-Tg mice treated with 10
and 50 ng/kg of DT were decreased to approximately 60
and 5–7% of control mice, respectively (Fig. 2D). These
results suggested that this transgenic mouse model is a
useful tool for evaluating the physiologic role of circulat-
ing ghrelin.
Histological analysiswith hematoxylin and eosin stain-
ing revealed that no inflammatory cell infiltration was
seen in the stomach (Fig. 2A), small intestine, colon, pan-
creas, pituitary, and hypothalamus of the GPDTR-Tg
mice with 50 ng/kg of DT injection. Other historical ab-
normalities were also not observed in these tissues (data
not shown).
The effects of a reduction in circulating ghrelin
after weaning on the GH/IGF-I axis and somatic
growth
To study the effects of postweaning reductions in cir-
culatingghrelinon theGH/IGF-I axis and somatic growth,
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FIG. 2. Ablation of ghrelin-secretion cells. Eight-week-old male
GPDTR-Tg mice (Tg) and nontransgenic littermates (WT) were
injected with saline or 10 or 50 ng/kg of DT (im) on d 0 and 2, then
analyzed on d 4. A, Histological analysis of stomach sections.
Immunohistochemical analysis of ghrelin peptide expression and
hematoxylin and eosin staining. Original magnification, 100. B,
Ghrelin mRNA levels in the stomach. C, Ghrelin mRNA levels in the
duodenum, pancreas, pituitary, and hypothalamus of GPDTR-Tg and WT
mice injected with 50 ng/kg of DT. D, Plasma ghrelin levels in GPDTR-Tg
and WT mice. For B–D, data represent the means SEM (n 8).
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(50 ng/kg) or saline twice a week for 5 wk (from 3 to 8
wk old). After DT injection, plasma ghrelin levels of
GPDTR-Tg mice decreased rapidly. In GPDTR-Tg mice,
ghrelin levelswereundetectableby5wkofage, remaining so
thereafter (Fig. 3A). The data obtained from GPDTR-Tg
mice were compared with those from three groups of con-
trol mice (WT with saline, WT with DT, and GPDTR-Tg
with saline).
To elucidate whether a postweaning reduction in cir-
culating ghrelin can influence GH secretion, we measured
basal serumGHlevels andperformedGHprovocative test
withGHRH.Therewere nodifferences inbasal serumGH
levels betweenGPDTR-Tgmice treated with DT and con-
trolmice in eithermales or females at 5 or 8wkof age. GH
provocative test with GHRH showed some intriguing
results (Fig. 3B). The GH responses to GHRH in male
GPDTR-Tgmice treatedDTwere significantly lower than
those in three controls at 5 wk of age. However, those
responses were normalized at 8 wk of age. On the other
hand, there were no differences in GH response to GHRH
among four groups (WT with saline or DT, and Tg with
saline or DT) in females at 5 or 8 wk of age.
To elucidate whether temporarily attenuation of GH
responses to GHRH can affect IGF-I regulation, we in-
vestigated serum IGF-I levels and IGF-I mRNA expres-
sions in the liver, skeletal muscle, and distal
femur. There were no differences in serum
IGF-I levels among any animal groups in ei-
ther males or females at 5 or 8 wk of age (Fig.
3C). There were also no differences in IGF-I
mRNA expressions in the liver, skeletal mus-
cle, or distal femur among any animal groups
at 5wk of age (Fig. 3D).We then investigated
the effects of decreases in circulating ghrelin
on the expression ofmRNAencodingGHRH
and SST within the hypothalamus and en-
coding GH and GHS-R in the pituitary.
There were no differences in mRNA expres-
sion levels of these mediators among any an-
imal groups inmale and female at 5 wk of age
(Fig. 4).
As expected from the results of the IGF-I
studies, no evidence of growth retardation
could be found in either male or female GP-
DTR-Tg mice treated with DT during the ob-
servation period. There were no difference in
body weight or length in comparison with
three groups of controlmice at anypoint (Fig. 5,
AandB, formale; andFig. 5,DandE, for female
animals). CTanalysis of body composition dem-
onstrated that there were no differences in per-
cent fat or BMD among any animal groups at 5
and 8 wk of age (Fig. 5C for male, and Fig. 5F for female
animals).
There were no differences in weekly food intake from
3 to 8 wk of age [WT vs. GPDTR-Tg (treated with DT);
male, 18.4  0.5 vs. 18.9  0.7; female, 18.4  1.0 vs.
18.5 0.6 (g/wk)]. These results suggested that although
GH responses to GHRHwere temporarily reduced under
conditions of decrease in circulating ghrelin, somatic








































































WT Tg WT Tg WT Tg WT Tg
5w 8w 5w 8w
male female



































































WT Tg WT Tg WT Tg WT Tg WT Tg WT Tg
liver muscle femur liver muscle femur
male female






























WT with saline WT with DT




Minutes after GHRH injection (min)
A B
C D
FIG. 3. The effects of a postweaning reduction in circulating ghrelin on the GH/IGF-I
axis. Three-week-old GPDTR-Tg and WT mice were injected saline or DT at a dose of
50 ng/kg twice a week for 5 wk (from 3 to 8 wk old). A, Plasma ghrelin levels before
and after DT injection. B, GH response to GHRH administration (180 g/kg sc) in
GPDTR-Tg and WT mice at 5 and 8 wk of age. C, Serum IGF-I levels of GPDTR-Tg
and WT mice at 5 and 8 wk of age. D, IGF-I mRNA levels in liver, skeletal muscle,
and femur in GPDTR-Tg and WT mice at 5 wk of age. Data represent the means 








































































































FIG. 4. The effects of a postweaning reduction in circulating ghrelin
on the expression of mRNA encoding GHRH, SST,GH and GHS-R.
Three-week-old GPDTR-Tg and WT mice were injected saline or DT at a
dose of 50 ng/kg twice a week for 5 wk (from 3 to 8 wk old). Pituitary
mRNA levels of GH and GHS-R and hypothalamic mRNA levels of
GHRH and SST in GPDTR-Tg and WT mice at 5 wk of age. Data
represent the means  SEM (n  12).
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GH response to GHRH in the ghrelin-rescued
GPDTR-Tg mice
ToelucidatewhetherGHresponsiveness toGHRHcan
be ameliorated by ghrelin replacement in the ghrelin-ab-
lated mice, GH provocative test were carried out in the
DT-treated GPDTR-Tg mice whose circulating ghrelin
were rescued by continuously administration of ghrelin
with osmotic pump. The average plasma ghrelin levels
during continuous infusion of ghrelin were 31.6  5.3
fmol/ml in the DT-treated GPDTR-Tg mice, whereas
those without ghrelin infusion were 1.7  0.2 fmol/ml.
GH provocative test were carried out at the age of 5 wk.
GH responsiveness to GHRH was ameliorated by gh-
relin replacement. Serum GH levels at 0, 15, and 30 min
after GHRH administration in the ghrelin-rescued mice
were 7.8  1.6, 26.2  4.2, and 12.3  0.8 ng/ml,
respectively, whereas those in mice without ghrelin re-
placement were 6.8  1.5, 10.9  2.6, and 11.3  1.6
ng/ml, respectively. These results suggested that atten-
uated response to GHRH seen in ghrelin-ablated mice
without ghrelin replacement was due to acute ghrelin
deficiency.
Discussion
In this study, we generated transgenic
mice expressing the DTR driven by the
transcriptional regulatory machinery of
ghrelin. Injection of DT into this mouse
can ablate ghrelin-secreting cells. Ap-
proximately 70–80%of circulating gh-
relin originates from the stomach (13).
Ghrelin-producing cells are also found
throughout the small intestine, with the
duodenum producing approximately
one-tenth that of the stomach (14).
Semiquantitative PCR revealed that
DTRwasonly expressed in stomachand
not in pituitary, hypothalamus, and
pancreas and the intensity of the bandof
DTR in stomach was very low. Three
possibilities might be considered to ex-
plain this result. The first is the low ef-
ficiency of gene transfection. Three lines
ofGPDTR-Tgmice thatwe generated in
this study were inserted with low copy
numbers of transgene (DTR cDNA).
Thus, the expression levels of DTR
mRNA could be very low even in stom-
ach. The second is the efficiency of gene
expression. In this study, we designed a
fusion gene comprising the 4085-bp
fragment contained a partial sequence
of the 5-flanking region of the human
ghrelin gene and human DTR. The efficiency of gene ex-
pressiondrivenby this fragmentmight be lower than those
driven by the original ghrelin promoter region. The last,
except gastrointestinal tract, transcription of ghrelin gene
might be driven by a different size of fragment of the 5-
franking region. Immunohistochemical and PCR analyses
demonstrated that ghrelin-secreting cells in the stomach and
duodenumwere ablated after DT injection into GPDTR-Tg
mice, resulting inmarked reduction of plasma ghrelin levels.
In contrast, ghrelin-producing cells of the pituitary and hy-
pothalamus were unaffected. Thus, this transgenic mouse is
a useful model to explore the role of circulating ghrelin, be-
cause plasma ghrelin levels can be abrogated in a controlled
mannerwithout altering pituitary and hypothalamic ghrelin
mRNA expression levels.
The physiologic roles of ghrelin in the regulation ofGH
secretion remain unclear, because previous reports using
rodents deficient or reduced in ghrelin signals have given
conflicting results (7, 8, 15, 16). Sun et al. (7) reported that
ghrelin-deficient mice did not exhibit any growth retar-
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FIG. 5. The effects of a postweaning reduction in circulating ghrelin levels on somatic
growth. Three-week-old GPDTR-Tg and WT mice were injected saline or DT at a dose of
50 ng/kg twice a week for 5 wk (from 3 to 8 wk old). A and D, Changes in body weight
in male (A) and female mice (D). B and E, Nose to anus length in male (B) and in female
mice (E) at 5 and 8 wk of age. C and F, Body composition (% Fat) and BMD as analyzed by
CT in male (C) and in female mice (F) at 5 and 8 wk of age. Data represent the means  SEM
(n  12).
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(15) also were unable to observe any significant differences
between ghrelin-deficientmice andWTmice in bodyweight
or basal serum GH levels, when fed a standard diet. More-
over, Zigman et al. (16) demonstrated there was no signifi-
cantdifference inserumIGF-I levelsbetweenghrelinreceptor
knockout andWTmice. Sun et al. (8), however, showed that
ghrelin receptor knockout mice exhibited only a small re-
duction in body weight and serum IGF-I levels. In addition,
Panteletal. (5) showedthat twounrelatedfamilieswithshort
statue have a missense mutation of GHS-R. This mutation
impairs the constitutive activity of the GHS-R. They also
reported a young patient with growth delay who has a re-
cessive partial isolated GH deficiency due to GHS-R muta-
tions (17). These results indicate importance of ghrelin/
GHS-R signals in GH secretion and somatic growth.
The purpose of this study is to evaluate whether an
absence of circulating ghrelin can influence GH secretion
and somatic growth via GH/IGF-I axis inmammals. First,
we investigated basal serum GH levels and the GH re-
sponse to GHRH. Although basal serum GH levels in the
ghrelin-abrogated mice did not differ from those seen in
WTmice, theGHresponses toGHRHinmaleGPDTR-Tg
mice were significantly lower than those in WT mice at 5
wk of age. As coadministration of GHRH and ghrelin
produces synergistic effects on pituitary GH release (4),
circulating ghrelin may play a role in augmentation of
GHRH-stimulatedGHpulses. Indeed,GHresponsiveness
to GHRH was ameliorated by ghrelin replacement in the
ghrelin-ablated mice. However, the attenuated response
to GHRH in the ghrelin-ablated mice had persisted only
for a short term. The GH responses to GHRH in male
GPDTR-Tg mice were recovered and were not different
from those in WT mice at 8 wk of age. It is possible that
an adaptation to reduced circulating ghrelin occurred
within a short term. Indeed, Popovic et al. (18) reported
that 10 patients who underwent total-gastrectomy at least
2 yr ago, a state of acquired chronic hypoghrelinemia,
exhibited normal GH response to GHRH compared
with normal subjects. Meanwhile, in female mice, there
were no differences in either basal serum GH levels or
GH response to GHRH between WT and GPDTR-Tg
mice at 5 or 8 wk of age. The secretory pattern of GH
in rodents is sexually differentiated. In male rats, GH is
secreted in episodic pattern with low levels between
pulses, whereas in females, the pulses are lower and
plasma GH levels between pluses are higher than males
(19). The secretory pattern of GH differs between male
and female by 30 d of age (20). Gonadal steroids are
thought to produce the sexual differences in GH secre-
tion. We assumed that the sexual differences in GH
response to GHRH in ghrelin-ablated mice may depend
on gonadal steroids.
As GH secretion is pulsatile in nature, a single mea-
surement of GH concentration in blood would not ade-
quately reflect endogenous GH secretion. To estimate the
amplitude and frequency of GH pulses, short-interval
blood sampling under a conscious state is required. Such
studies are difficult to perform in mice. Instead, we inves-
tigated serum IGF-I levels, skeletal muscle IGF-I mRNA
expression, and anthropometric parameters that reflect
pulsatile GH release under similar nutritional conditions
(21). Serum IGF-I levels and IGF-I mRNA expression in
skeletal muscle did not decrease in the ghrelin-abrogated
mice in comparison with WT mice. These results suggest
that circulating ghrelin does not play a dominant role in
the GH/IGF-I axis. Due to significant differences between
species in the regulation of GH secretion (21), we have to
give careful considerations to apply the results of animal
experiments concerning GH secretion directly to humans;
insulin-induced hypoglycemia is a potent stimulus of GH
secretion in humans, whereas rats respond to the stress of
hypoglycemia by decreasing GH secretion (22, 23). L-ar-
ginine is a potent GH secretagogue in humans, but does
not (or less overtly) stimulateGHsecretion in rats (21, 24).
Somatic growth is affected not only by GH and IGF-I
but also by thyroid hormones, sex steroids, and glucocor-
ticoids. It also depends on genetic background and nutri-
tion. Adequate nutrition is one of the most important fac-
tors affecting somatic growth. In present study, therewere
no differences in food intake between the ghrelin-abro-
gated mice and WT mice. Body weight, length, and body
composition also were not influenced by plasma ghrelin
levels. These results suggest that circulating ghrelin does
not play a dominant role in somatic growth.
We cannot exclude the possibility that hypothalamic
ghrelinmay regulateGHsecretion, as hypothalamic ghrelin-
secreting cells were preserved in this animal model. Shuto et
al. (25) demonstrated that transgenic rats expressing anti-
sense GHS-R mRNA within the arcuate nucleus of the hy-
pothalamus displayed growth retardation, suggesting that
ghrelin/GHS-R systems in the hypothalamus function in the
regulation ofGH. Further studieswill be needed to elucidate
the role of hypothalamic ghrelin in GH secretion.
In summary, we have succeeded in generating transgenic
mice in which circulating ghrelin can be abrogated in a con-
trolled manner after birth. Our results suggest that circulat-
ing ghrelin does not play a crucial role in somatic growth.
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